EX-10.35 CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk ("[****]") to denote where omissions have been...License and Option Agreement • December 15th, 2006 • MetaMorphix Inc. • Pharmaceutical preparations • Delaware
ContractLicense and Option Agreement • May 5th, 2020 • New York
EX-10.1 2 xlrn-20180630xexhibit101.htm EXHIBIT 10.1 Exhibit 10.1 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATION August 2, 2011 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. TABLE OF CONTENTS
EX-10.1 2 d255800dex101.htm EX-10.1 CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS OMITTED IN THE EDGAR...License and Option Agreement • May 5th, 2020
This LICENSE AND OPTION AGREEMENT (the “Agreement”) is entered into as of July 27, 2016 (the “Effective Date”) by and between PFENEX INC., a Delaware corporation, with its principal place of business at 10790 Roselle Street, San Diego, CA 92121 (“Pfenex”), and JAZZ PHARMACEUTICALS IRELAND LIMITED, a limited liability company incorporated under the laws of Ireland, with a registered office at Fourth Floor, Connaught House, One Burlington Road, Dublin 4, Ireland (“Jazz”). Pfenex and Jazz are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENTLicense and Option Agreement • March 16th, 2021 • Curis Inc • Biological products, (no disgnostic substances)
This First Amendment to Collaboration, License and Option Agreement (the “Amendment”) is entered into as of September 7, 2016 (the “Amendment Date”), by and between Aurigene Discovery Technologies Limited, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and Curis, Inc., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (“Curis”).
CONFIDENTIAL TREATMENT REQUESTED LICENSE AND OPTION AGREEMENT between EMORY UNIVERSITY and ALIMERA SCIENCES, INC. for TRIPHENYLMETHANE COMPOUNDSLicense and Option Agreement • April 16th, 2010 • Alimera Sciences Inc • Pharmaceutical preparations • Georgia
THIS LICENSE AND OPTION AGREEMENT is made and entered into as of the 31st day of August, 2009, (hereinafter referred to as the “Effective Date”) by and between EMORY UNIVERSITY, a nonprofit Georgia corporation with offices located at 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (hereinafter referred to as “EMORY”) and Alimera Sciences, Inc., a Delaware corporation having a principal place of business located at 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30024 (hereinafter referred to as “ALIMERA”).
LICeNSE AND OPTION AGREEMENT BY AND BETWEENLicense and Option Agreement • February 16th, 2017 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (this “Agreement”) is made and effective as of the Effective Date (as defined below) by and between TRACON Pharmaceuticals, Inc., a Delaware corporation (“TRACON”) and Janssen Pharmaceutica N.V. (“Janssen”). Each of TRACON and Janssen is sometimes referred to herein individually as a “Party” and collectively as the “Parties.” In the event a Party assigned the License and Option Agreement (as defined below) in its entirety prior to the Effective Date (as defined below) pursuant to Section 13.6 of the License and Option Agreement, or a lawful successor of a Party became bound by the License and Option Agreement prior to the Effective Date, the references to such Party in this Agreement shall be deemed to refer to such permitted assignee or lawful successor.
EX-10.2 2 dex102.htm LICENSE AND OPTION AGREEMENT, DATED AS OF APRIL 11, 2007 EXECUTION COPY Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting...License and Option Agreement • May 5th, 2020 • New York
Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
AMENDED AND RESTATED LICENSE AND OPTION AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and SURROZEN for Llama Single Domain Antibody Phage Library UC Case No. [****]License and Option Agreement • June 24th, 2021 • Consonance-HFW Acquisition Corp. • Biological products, (no disgnostic substances) • California
This amended and restated license and option agreement (“Agreement”) is effective this 17th day of January, 2020 (“Amended and Restated Effective Date”), between The Regents of the University of California (“The Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, and acting through its Office of Technology Management, University of California San Francisco, 600 16th Street, Suite S-272, San Francisco, CA 94143 and Surrozen, Inc., a Delaware corporation, having a principal place of business at171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080 (“Surrozen”). The Regents and Surrozen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AND OPTION AGREEMENT BY AND BETWEEN MEDIMMUNE, LLC AND BULLDOG PHARMACEUTICALS, INC.License and Option Agreement • September 12th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Option Agreement (this “Agreement”) is entered into and made effective as of the 24th day of July, 2013 (the “Effective Date”), by and between MedImmune, LLC, a limited liability company organized and existing under the laws of Delaware, having a principal office located at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”), and Bulldog Pharmaceuticals, Inc., a company organized and existing under the laws of the British Virgin Islands, having a registered office located at Midocean Chambers, Road Town, Tortola, British Virgin Islands (“Kolltan”). MedImmune and Kolltan are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
ContractLicense and Option Agreement • March 21st, 2024 • Autolus Therapeutics PLC • Biological products, (no disgnostic substances)
LICENSE AND OPTION AGREEMENT by and between SPARK THERAPEUTICS, INC. and SELECTA BIOSCIENCES, INC. December 2, 2016License and Option Agreement • February 14th, 2017 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
This License and Option Agreement (hereinafter “Agreement”), effective as of December 2, 2016 (the “Effective Date”), is made by and between Spark Therapeutics, Inc., a Delaware corporation with corporate offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Spark”) and Selecta Biosciences, Inc., a Delaware corporation with corporate offices at 480 Arsenal Street, Building One, Watertown, MA 02472 (“Selecta”) (each, a “Party” and collectively, the “Parties”).
LICENSE and OPTION AGREEMENT BRIGHAM YOUNG UNIVERSITY and ARIDIS, LLCLicense and Option Agreement • July 18th, 2018 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations • Utah
This Agreement, effective July 29, 2005 is entered into between Brigham Young University, a Utah non-profit corporation and institution of higher education, with its principal campus and place of business located at Provo, Utah 84602 (referred to in this Agreement as “BYU”) and Aridis, LLC, a California corporation with its principal place of business located at 350 Cervantes Road, Portola Valley, CA 94028, (referred to in this Agreement as “LICENSEE”).
RECITALSLicense and Option Agreement • January 28th, 2000 • Abgenix Inc • Biological products, (no disgnostic substances) • California
LICENSE AND OPTION AGREEMENT by and between SPARK THERAPEUTICS, INC. and SELECTA BIOSCIENCES, INC. December 2, 2016License and Option Agreement • February 28th, 2017 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This License and Option Agreement (hereinafter “Agreement”), effective as of December 2, 2016 (the “Effective Date”), is made by and between Spark Therapeutics, Inc., a Delaware corporation with corporate offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Spark”) and Selecta Biosciences, Inc., a Delaware corporation with corporate offices at 480 Arsenal Street, Building One, Watertown, MA 02472 (“Selecta”) (each, a “Party” and collectively, the “Parties”).
AMENDMENT NO. 2 TO THE LICENSE AND OPTION AGREEMENTLicense and Option Agreement • May 11th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS AMENDMENT NO. 2 TO THE LICENSE AND OPTION AGREEMENT (“Amendment”) is made and entered into as of December 6, 2002, by and among GeneSoft Pharmaceuticals, Inc., a Delaware corporation (the “GS”), and LG Life Sciences, Ltd., a corporation organized under the laws of the Republic of Korea (“LGLS”). Capitalized terms not otherwise defined in this Amendment shall have the meaning given them in that certain License and Option Agreement by and among GS and LGLS dated as of October 22, 2002 (the “Agreement”).
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • September 21st, 2005 • Reading International Inc • Operators of apartment buildings
THIS AGREEMENT, dated as of the 19th day of September, 2005 by and between SUTTON HILL PROPERTIES, LLC, a Nevada limited liability company, having an office at c/o Reading International Inc. 500 Citadel Drive, Suite 300, Commerce, CA 90040 (the “Licensor”), and SUTTON HILL CAPITAL L.L.C., a New York limited liability company, having an office at 120 North Robertson Blvd., 3rd Floor, Los Angeles, CA 90048 (the “Licensee”).
RECITALSLicense and Option Agreement • August 12th, 1998 • Astra Ab /Adr/ • New York
Amendment Number 1 to Research, Co-Development and Commercialization Agreement and Research License and Option AgreementLicense and Option Agreement • March 16th, 2007 • Neose Technologies Inc • Medicinal chemicals & botanical products
This Amendment Number 1 (the “Amendment”) to the Collaboration Agreement and the License Agreement (both as defined below) is effective as of October 20, 2006 (the “Effective Date”), and is by and between BioGeneriX AG, a corporation organized under the laws of the Federal Republic of Germany (“BioGeneriX”), and Neose Technologies, Inc., a corporation organized and existing under the laws of the state of Delaware (“Neose”).
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • November 4th, 2009 • Cornerstone Therapeutics Inc • Pharmaceutical preparations • California
THIS LICENSE AND OPTION AGREEMENT (the “Agreement”) is made this 22nd day of October, 2002 (the “Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
RECITALSLicense and Option Agreement • January 28th, 1997 • Antivirals Inc
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • April 28th, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • New York
This LICENSE AND OPTION AGREEMENT (this “Agreement”) is entered into and made effective as of February 27, 2023 (the “Effective Date”), by and between ImmunoGen, Inc., a Massachusetts corporation, having its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451 (“ImmunoGen”), and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, having its principal place of business at 50 Northern Avenue, Boston, MA 02210 (“Vertex”). ImmunoGen and Vertex will be referred to herein individually as a “Party” and collectively as the “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. LICENSE AND OPTION AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND MACROGENICS, INC. MAY 22, 2014License and Option Agreement • August 5th, 2014 • Macrogenics Inc • Pharmaceutical preparations • New York
THIS AGREEMENT (“Agreement”) is entered into as of May 22, 2014 (the “Effective Date”), by and between TAKEDA PHARMACEUTICAL COMPANY LIMITED, a corporation organized under the laws of Japan, having its principal place of business at 1-1 Doshomachi 4-chome, Chuo-ku, Osaka, Japan (hereinafter “Takeda”) and MACROGENICS, INC, a Delaware corporation having its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850 (hereinafter “MacroGenics”). Takeda and MacroGenics are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • May 11th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS LICENSE AND OPTION AGREEMENT (the “Agreement”) is made this 22nd day of October, 2002 (the “Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO LICENSE AND OPTION AGREEMENTLicense and Option Agreement • May 11th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances
THIS AMENDMENT NO. 1 TO LICENSE AND OPTION AGREEMENT (the “Amendment”) is made and entered into this 21st day of November, 2002 (the “Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS may be referred to herein individually as a “Party” and collectively as the “Parties.”
THIRD Amendment to Collaboration, LICENSE and Option AgreementLicense and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Third Amendment to the Collaboration, License and Option Agreement (the “Third Amendment”) is entered into as of October 29, 2019 (the “Third Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED...License and Option Agreement • February 28th, 2022 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Commercial License and Option Agreement (the “CLOA”) is effective as of November 22, 2021 (the “Amendment Date”), by and between Synaffix B.V., with an office at Pivot Park Oss, Noord-Brabant, Kloosterstraat 9, 5349 AB, Oss, The Netherlands (“SNFX”) and Mersana Therapeutics, Inc., with an office at 840 Memorial Drive, Cambridge, Massachusetts 02139, USA (“MERSANA”). SNFX and MERSANA are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.” This CLOA amends and restates in its entirety that certain Commercial License and Option Agreement, dated as of January 3, 2019 (the “Effective Date”), by and between the Parties (the “Original Agreement”), pursuant to Section 11.2 thereof.
COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATIONLicense and Option Agreement • August 4th, 2016 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
This Collaboration, License and Option Agreement (this “Agreement”) dated the 20th day of February, 2008 (the “Execution Date”) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 149 Sidney Street, Cambridge, MA 02139 (“Acceleron”), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (“Celgene”). Acceleron and Celgene may each be referred to herein individually as a “Party” and collectively as the “Parties.”
HCV PROBE LICENSE AND OPTION AGREEMENT— EUROPEAN UNIONLicense and Option Agreement • August 12th, 2003 • Chiron Corp • Pharmaceutical preparations
This agreement (hereinafter "Agreement") is made by and between CHIRON CORPORATION, a Delaware corporation, of 4560 Horton Street, Emeryville, California 94608 (hereinafter referred to as "CHIRON"), F. HOFFMANN-LA ROCHE LTD., a Swiss corporation, of Grenzacherstrasse 124, Basel, Switzerland (hereinafter referred to as "ROCHE PARENT"), and ROCHE MOLECULAR SYSTEMS, INC., a Delaware corporation, of 1145 Atlantic Avenue, Suite 100, Alameda, California 94501 (hereinafter referred to as "RMS" and collectively with ROCHE PARENT, "ROCHE").
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • December 3rd, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS LICENSE AND OPTION AGREEMENT (the “Agreement”) is made this 22nd day of October, 2002 (the “Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT OF COMMERCIAL LICENSE AND OPTION AGREEMENTLicense and Option Agreement • March 23rd, 2009 • Biotime Inc • Biological products, (no disgnostic substances)
This First Amendment of Commercial License and Option Agreement is made effective the 11th day of March 2009 (“Amendment Date”), by and between the Wisconsin Alumni Research Foundation (hereinafter called “WARF”), a nonprofit Wisconsin corporation, and BioTime, Inc. (hereinafter called “Licensee”), a corporation organized and existing under the laws of California.
AMENDMENT NO. 2 TO THE LICENSE AND OPTION AGREEMENTLicense and Option Agreement • December 3rd, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS AMENDMENT NO. 2 TO THE LICENSE AND OPTION AGREEMENT (“Amendment”) is made and entered into as of December 6, 2002, by and among GeneSoft Pharmaceuticals, Inc., a Delaware corporation (the “GS”), and LG Life Sciences, Ltd., a corporation organized under the laws of the Republic of Korea (“LGLS”). Capitalized terms not otherwise defined in this Amendment shall have the meaning given them in that certain License and Option Agreement by and among GS and LGLS dated as of October 22, 2002 (the “Agreement”).
LICENSE AND OPTION AGREEMENT This License and Option Agreement (the "Agreement") is entered into as of January 1, 1999, by and between ValueClick, LLC, a California limited liability company (the "Licensor") and ValueClick Japan Inc., a Japanese joint...License and Option Agreement • October 12th, 1999 • Valueclick Inc/Ca
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO MERSANA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED COMMERCIAL LICENSE AND OPTION...License and Option Agreement • August 7th, 2020 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
COLLABORATION, LICENSE AND OPTION AGREEMENTLicense and Option Agreement • March 19th, 2020 • Curis Inc • Biological products, (no disgnostic substances)
This Second Amendment to Collaboration, License and Option Agreement (this “Second Amendment”) is entered into as of February 5, 2020 (the “Second Amendment Date”), by and between Aurigene Discovery Technologies Limited, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and Curis, Inc., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (“Curis”).
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • June 26th, 2008 • CSMG Technologies, Inc. • Surgical & medical instruments & apparatus • Ontario
Carbon Capture Technologies, Inc. (CCTI *) (hereinafter referred to as the "LICENSEE") with its principal place of business at 2109 E. Palm Avenue, Tampa, Florida 33605 , and University of Ottawa, hereinafter referred to as the "LICENSOR"), and with its principal place of operation at 3042-800 King Edward Avenue, SITE, Ottawa, Ontario K1N 6N5 Canada.
